Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

MLA

Omuro, Antonio, et al. “Methotrexate and Temozolomide versus Methotrexate, Procarbazine, Vincristine, and Cytarabine for Primary CNS Lymphoma in an Elderly Population: An Intergroup ANOCEF-GOELAMS Randomised Phase 2 Trial.” The Lancet. Haematology, vol. 2, no. 6, June 2015, pp. e251–59. EBSCOhost, https://doi.org/10.1016/S2352-3026(15)00074-5.

APA

Omuro, A., Chinot, O., Taillandier, L., Ghesquieres, H., Soussain, C., Delwail, V., Lamy, T., Gressin, R., Choquet, S., Soubeyran, P., Huchet, A., Benouaich-Amiel, A., Lebouvier-Sadot, S., Gyan, E., Touitou, V., Barrié, M., del Rio, M. S., Gonzalez-Aguilar, A., Houillier, C., … Hoang-Xuan, K. (2015). Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. The Lancet. Haematology, 2(6), e251–e259. https://doi.org/10.1016/S2352-3026(15)00074-5

Chicago

Omuro, Antonio, Olivier Chinot, Luc Taillandier, Hervé Ghesquieres, Carole Soussain, Vincent Delwail, Thierry Lamy, et al. 2015. “Methotrexate and Temozolomide versus Methotrexate, Procarbazine, Vincristine, and Cytarabine for Primary CNS Lymphoma in an Elderly Population: An Intergroup ANOCEF-GOELAMS Randomised Phase 2 Trial.” The Lancet. Haematology 2 (6): e251–59. doi:10.1016/S2352-3026(15)00074-5.